How does lenvatinib affect enzyme systems in the body?

Lenvatinib (Lenvatinib) is a multi-target tyrosine kinase inhibitor (TKI), mainly used to treat hepatocellular carcinoma (HCC), thyroid cancer and renal cell carcinoma. It prevents tumor angiogenesis and inhibits cancer cell proliferation by inhibiting signaling pathways such as vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR). In the body, the metabolism of lenvatinib is closely related to the enzyme system, especially the metabolic enzymes such as cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).

First, the main metabolic pathway of lenvatinib involves the CYP3A4 enzyme in the liver. CYP3A4 is one of the most important drug metabolizing enzymes in the body, responsible for the oxidative metabolism of lenvatinib, converting it into metabolites that are easier to excrete. Therefore, any factors that affect CYP3A4 activity, such as strong CYP3A4 inhibitors (such as ketoconazole) or inducers (such as rifampicin), may alter the plasma concentration of lenvatinib. For example, CYP3A4inhibitors may reduce the metabolism of lenvatinib, leading to increased plasma concentrations and increased risk of toxicity, while CYP3A4 inducers may accelerate its metabolism and reduce drug efficacy.

Secondly, in addition to the CYPenzyme system, lenvatinib can also be metabolized through non-CYPenzyme pathways, such as UDP-glucuronosyltransferase (UGT)-mediated glucuronidation reaction. This metabolic mode may play an important role in some patients, especially when CYP3A4 activity is impaired, UGT metabolic pathway may become a complementary metabolic pathway. UGTChanges in the enzyme system may also affect the clearance rate of lenvatinib, thus affecting its efficacy and incidence of adverse reactions.

In addition, lenvatinib may indirectly affect the metabolic system in the body by inhibiting the activity of certain enzymes. For example, it may affect the function of the liver enzyme system, leading to an increase in liver enzymes (such as ALT, AST). This is one of the reasons why patients need to monitor liver function during treatment. In addition, the metabolic processes of certain drugs may be further altered due to its effects on the renal and bile excretion systems. Therefore, when using lenvatinib, potential drug interactions need to be carefully evaluated and the dose adjusted according to individual metabolic conditions to optimize therapeutic effects and reduce adverse reactions.

Reference materials:https://www.lenvima.com/